Nancy Doyle was hired at Charles River as an animal health technician in Musculoskeletal research in 1996, while she was completing her bachelor’s degree in biology. Once she graduated from the University of Québec in Montréal (UQAM) in 1998, she was promoted as Study Director within the Musculoskeletal Research group.
During the 20 years she was Study Director, she was responsible in the design and execution of toxicology studies with bone endpoints that included most model species and route of administrations using model ages representing juvenile to geriatric populations. She has experience in preclinical imaging, bone biomarkers, biomechanics in musculoskeletal research, and toxicology with a wide range of orthopedic and disease models (ex: osteotomy, critical size bone defect, OVX, ORX, CIA, TPTx) and medical device in the different species.
She joined the Scientific Advisor Services group of Charles River in 2018 where her role was to guide clients designing their preclinical program to address regulatory and scientific questions for a wide variety of small molecule drugs, biologics, and medical devices. Nancy then moved to the Boisbriand, Québec Site (a dedicated medical device testing site of Charles River) where she continued providing scientific and regulatory advice for medical device development.
She is now Strategic Client Manager in Toxicology for the Canadian sites and thanks to her experience and in-depth understanding of regulatory guidelines, she continues providing scientific advice to clients. She has also co-authored several research papers in peer reviewed scientific journals related to musculoskeletal research, including cartilage research and Toxicology, and co-authored a chapter to a book on bone toxicology.